Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Ezetimibe (Zetia) vs MitoQ: MitoQ has the stronger overall evidence (5 vs 4.4/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
MitoQ wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Ezetimibe (Zetia) and MitoQ have evidence — compare verdict strength side-by-side.
10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.
Any time of day
Oral tablet (ezetimibe 10 mg)
10-20mg daily
Morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
and 1 more not shown
2–4 weeks
Months to years
Throughout use
Throughout use
Acute to 6 weeks
4 weeks
12 months
3 weeks
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
The New England journal of medicine (2015) · Rct · n=18144
IMPROVE-IT randomized trial: ~18,000 patients stabilized after acute coronary syndromes
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet (London, England) (2011) · Rct · n=9438
SHARP randomized placebo-controlled trial in chronic kidney disease (n≈9,400)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
The New England journal of medicine (2008) · Rct · n=1873
SEAS randomized trial in patients with mild-to-moderate aortic stenosis
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
MitoQ has a higher evidence score (5/10 vs 4.4/10) and wins in 2 of 3 categories.
For support heart health, Ezetimibe (Zetia) has a higher relevance score (68 vs 60).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.